Satisfying needs for
niche Specialty Care products
00 / pharma& news
19/04/2021
pharma& is happy to announce that a share purchase agreement with Zatortia Holdings Ltd., Limassol, Cyprus (subsidiary of Shilpa Medicare Ltd., India) has been entered to acquire 100% of shares of LOBA Feinchemie GmbH, Fischamend, Austria.
This acquisition enables pharma& to vertically integrate a high-quality Active Pharmaceuticals Ingredient producer in order to secure long-term supply of its highly niche specialty care medicines. LOBA renews its firm commitment to the development and production of high quality Intermediates, Fine Chemicals and Active Pharmaceutical Ingredients and is looking forward to build upon the trusted and long-lasting customer relationships having been established in the past.
01 / pharma& is
pharma& is a privately owned company, aiming at satisfying needs for niche, original, Specialty Care products.
Our commitment to patient access for well-established original Specialty Care medicines and our worldwide presence of own subsidiaries, affiliated companies and partnerships, secure sustainable product availibilty in markets around the world.
02 / pharma& story
After having acquired multiple products in various therapeutic areas and having established a profound base to secure patient access and to supply products across the entire European Landscape we have expanded our footprint to serve patients around the world.
We are proud of our “every patient counts” commitment and our strong partnership network.
03 / pharma& team
All of us have been trained over decades in Top Tier Global Pharmaceutical Companies, coming together as a team, committed and enjoying to grow together.
Supported by our trusted network of highly qualified service providers and experts, we want to shape our future and to leave footprints for the benefits of our patients, their caregivers and our stakeholders.
04 / pharma& founders
Frank Rotmann
" Throughout my 20+ years
in the industry, I have developed a track record in building
and developing organisations
for growth! "
Elmar Zagler
" Having started my career in Finance, I know how to optimize businesses and
how to leverage
networks & alliances! "
05 / pharma& portfolio
05.1 / prescription medicines
05.2 / consumer health
05.3 / affiliated companies
06 / pharma& pharmacovigilance contact
IN GERMAN
Bei Nebenwirkungen wenden Sie sich bitte an
oder schreiben Sie ein Email an pv@drehm.at.
Zusätzlich können Sie auch direkt über die Homepage des Bundesamtes für Sicherheit im Gesundheitswesen (http://www.basg.gv.at) Nebenwirkungsfälle melden.
IN ENGLISH
In case of adverse events, please contact
or send an Email to pv@drehm.at.
Additionally, you can also report adverse events via your local health authorities.
IN DUTCH
Voor het melden van bijwerkingen, contacteer
of u kunt een e-mail sturen naar pharmacovigilance@bfc.nl.
Daarnaast kunt u bijwerkingen ook melden bij het Lareb, www.lareb.nl.